For the nine months ended September 30, 2026, Aligos Therapeutics reported a net loss of $46.4 million, a significant increase from the $4.3 million loss in the prior year period. While total revenue grew to $33.5 million due to a $27.8 million licensing agreement, the prior year's results were heavily skewed by a $59.0 million non-cash gain from the change in fair value of common warrants.
Aligos Therapeutics reported third quarter 2026 financial results, including a net loss of $21.9 million and a cash position of $31.1 million. The company highlighted clinical progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for a topline data readout in late Q3 2027. Current cash reserves are expected to fund operations into the first quarter of 2027.
“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027. With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”
Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer